Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Blood (2024) 144 (Supplement 1): 88.

https://doi.org/10.1182/blood-2024-205907

Published: 2024

Journal Articles

Development of an Ex Vivo Precision Gene Engineered B Cell Medicine That Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B

Hanlan Liu, Swati Singh, Timothy Mullen, Caroline Bullock, Sean Keegan, Troy Patterson, Amy Lundberg, Sakshisingh Thakur, Charuta Yadav, Shamael Dastagir, Lily Li, Wayne Bainter, Shalini Chilakala, Anja Hohmann, Adam Lazorchak, Richard A Morgan

Blood (2023) 142 (Supplement 1): 463.

https://doi.org/10.1182/blood-2023-182468

Published: 2023

Journal Articles

Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression

Ryan L. Wong, Sarah Sackey, Devin Brown, Shantha Senadheera, Katelyn Masiuk, Jason P. Quintos, Nicole Colindres, Luke Riggan, Richard A. Morgan, Harry L. Malech, Roger P. Hollis, Donald B. Kohn

Blood (2023) 141 (9): 1007–1022.

https://doi.org/10.1182/blood.2022016074

Published: 2023

Includes: Supplemental data

Journal Articles

Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment

Christopher M Borges, PhD BS, Kevin Wasko, Jared M Nasser, Kelly Donahue, Amanda Pfautz, Lincy P Antony, Glenn Leary, Steven Sexton, Richard A. Morgan, PhD, Karrie K Wong, PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-139988

Published: 2020

Journal Articles

Generation of Natural Killer Cells with Enhanced Function from a CRISPR/Cas12a-Edited Induced Pluripotent Stem Cell Line

Jung-Il Moon, PhD, Melissa S Chin, BS, Andrew T Burden, BS, Steven Sexton, Kevin Wasko, Jared M Nasser, Lincy P Antony, Karrie K Wong, PhD, Christopher M Borges, PhD BS, Richard A. Morgan, PhD, G. Grant Welstead, PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-139471

Published: 2020

Journal Articles

Knockout of CBLB Greatly Enhances Anti-Tumor Activity of CAR T Cells

Kathryn Hooper, PhD, Kyle Havens, PhD, Anne-Rachel Krostag, BS, Michael S Magee, PhD, Unja Martin, Ankit Gupta, PhD, Yegor Smurnyy, PhD, Lisa Pechilis, Amanda Rode, Andrew Chavkin, MS, Shannon Grande, PhD, Richard A. Morgan, PhD, Jordan Jarjour, PhD, Alexander Astrakhan, PhD

Blood (2018) 132 (Supplement 1): 338.

https://doi.org/10.1182/blood-2018-99-119247

Published: 2018

Journal Articles

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

James B Rottman, DVM, PhD DACVP, Kenneth Ganley, BS, Brenna Daly, BS, Holly M. Horton, PhD, Kevin M. Friedman, Molly Perkins, PhD, Shannon Grande, PhD, Claire J Rhodes, BS, Richard A. Morgan, PhD, Christopher J. Horvath, DVM, MS, DACVP

Blood (2017) 130 (Supplement 1): 4450.

https://doi.org/10.1182/blood.V130.Suppl_1.4450.4450

Published: 2017

Journal Articles

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Yi Lin, MD PhD, Noopur Raje, MD, Nikhil Munshi, MD, David Siegel, MD PhD, Michaela Liedtke, MD, Sundar Jagannath, MD, Marcela V. Maus, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Kristen Hege, MD, Richard A. Morgan, PhD, Michael Travis Quigley, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 740.

https://doi.org/10.1182/blood.V130.Suppl_1.740.740

Published: 2017

Journal Articles

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

Michael S Magee, PhD, Iulia Diaconu, PhD, Mark Pogson, PhD, Ankit Gupta, PhD, Amy Jensen-Smith, PhD, Brian Collette, BS, Andrew Chavkin, MS, Eli Pasackow, BS, Aaron Edwards, MS, Kevin M. Friedman, Alexander Astrakhan, PhD, Michael T Certo, PhD, Jordan Jarjour, PhD, Richard A. Morgan, PhD

Blood (2017) 130 (Supplement 1): 1906.

https://doi.org/10.1182/blood.V130.Suppl_1.1906.1906

Published: 2017

Journal Articles

A Novel TGF-β 2 /Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β 2 -Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks

Benjamin Boyerinas, Sara M. Miller, Ryan C. Murray, John W. Evans, Geoffrey B. Parsons, Katherine J. Seidl, Kevin M. Friedman, Richard A. Morgan, PhD

Blood (2017) 130 (Supplement 1): 1911.

https://doi.org/10.1182/blood.V130.Suppl_1.1911.1911

Published: 2017

Journal Articles

Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Graham Lilley, M.S., Alden Ladd, Daniel Cossette, Laura Viggiano, Gregory Hopkins, John W. Evans, PhD, Mingli Li, M.S., Howard J. Latimer, IV, BS, Sara M. Miller, Michael Kuczewski, MS, Wendy Bakeman, Kayla MacLeod, Kevin M. Friedman, PhD, Dawn A Maier, M.S., Michael Paglia, M.S., Richard A. Morgan, PhD, Mark D Angelino, PhD

Blood (2015) 126 (23): 3243.

https://doi.org/10.1182/blood.V126.23.3243.3243

Published: 2015

Journal Articles

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil., Shannon Grande, PhD, Amanda Hamel, BS, Holly M. Horton, PhD, Tracy E. Garrett, BA, Sara M. Miller, Howard J. Latimer, IV, BS, Christopher J. Horvath, DVM, MS, DACVP, Michael Kuczewski, MS, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 1893.

https://doi.org/10.1182/blood.V126.23.1893.1893

Published: 2015

Journal Articles

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Alena A. Chekmasova, PhD, Holly M. Horton, PhD, Tracy E. Garrett, BA, John W. Evans, PhD, Johanna Griecci, BS, Amanda Hamel, BS, Howard J. Latimer, IV, BS, Stacie L. Seidel, MA, Byoung Y. Ryu, PhD, Michael Kuczewski, MS, Christopher J. Horvath, DVM, MS, DACVP, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 3094.

https://doi.org/10.1182/blood.V126.23.3094.3094

Published: 2015

Journal Articles

Risky business: target choice in adoptive cell therapy

Richard A. Morgan

Blood (2013) 122 (20): 3392–3394.

https://doi.org/10.1182/blood-2013-09-527622

Published: 2013

Journal Articles

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

Daniel Abate-Daga, Ken-ichi Hanada, Jeremy L. Davis, James C. Yang, Steven A. Rosenberg, Richard A. Morgan

Blood (2013) 122 (8): 1399–1410.

https://doi.org/10.1182/blood-2013-04-495531

Published: 2013

Includes: Supplemental data

Journal Articles

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance M. Yuan, Ira H. Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas

Blood (2013) 121 (7): 1165–1174.

https://doi.org/10.1182/blood-2012-06-438002

Published: 2013

Includes: Supplemental data

Journal Articles

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

James N. Kochenderfer, Mark E. Dudley, Steven A. Feldman, Wyndham H. Wilson, David E. Spaner, Irina Maric, Maryalice Stetler-Stevenson, Giao Q. Phan, Marybeth S. Hughes, Richard M. Sherry, James C. Yang, Udai S. Kammula, Laura Devillier, Robert Carpenter, Debbie-Ann N. Nathan, Richard A. Morgan, Carolyn Laurencot, Steven A. Rosenberg

Blood (2012) 119 (12): 2709–2720.

https://doi.org/10.1182/blood-2011-10-384388

Published: 2012

Includes: Supplemental data

Journal Articles

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Rimas J Orentas, PhD, Waleed Haso, B.S., Richard A. Morgan, Ira Pastan, MD, Crystal L Mackall, MD

Blood (2011) 118 (21): 4313.

https://doi.org/10.1182/blood.V118.21.4313.4313

Published: 2011

Journal Articles

B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor

James N Kochenderfer, Mark E. Dudley, Steven Feldman, Wyndham H. Wilson, MD, PhD, David Spaner, Laura Devillier, Robert Carpenter, Debbie-Ann N. Nathan, Irina Maric, Richard A. Morgan, Steven A. Rosenberg

Blood (2011) 118 (21): 167.

https://doi.org/10.1182/blood.V118.21.167.167

Published: 2011

Journal Articles

Human effector CD8 + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

Christian S. Hinrichs, Zachary A. Borman, Luca Gattinoni, Zhiya Yu, William R. Burns, Jianping Huang, Christopher A. Klebanoff, Laura A. Johnson, Sid P. Kerkar, Shicheng Yang, Pawel Muranski, Douglas C. Palmer, Christopher D. Scott, Richard A. Morgan, Paul F. Robbins, Steven A. Rosenberg, Nicholas P. Restifo

Blood (2011) 117 (3): 808–814.

https://doi.org/10.1182/blood-2010-05-286286

Published: 2011

Includes: Supplemental data

NARROW

A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Development of an Ex Vivo Precision Gene Engineered B Cell Medicine That Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B

Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression

Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment

Generation of Natural Killer Cells with Enhanced Function from a CRISPR/Cas12a-Edited Induced Pluripotent Stem Cell Line

Knockout of CBLB Greatly Enhances Anti-Tumor Activity of CAR T Cells

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

A Novel TGF-β 2 /Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β 2 -Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks

Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Risky business: target choice in adoptive cell therapy

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor

Human effector CD8 + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only